- FDA approves Mekinist in combination with Tafinlar to treat patients with advanced melanoma
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- FDA approves combination of two GSK drugs for skin cancer
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
NEW YORK — Bristol-Myers Squibb will collaborate with Roche to investigate the use of a combination of the companies’ drugs in patients with a deadly form of skin cancer.
The companies will conduct a phase 1/2 trial to test the safety and efficacy of BMS’ Yervoy (ipilimumab) in combination with Roche’s investigational drug vemurafenib in patients with melanoma that has spread to other parts of the body.
“Metastatic melanoma is one of the most aggressive forms of cancer,” BMS SVP development and medical affairs Brian Daniels said. “We are excited to be working with Roche to evaluate the potential that together; Yervoy and vemurafenib could improve outcomes for melanoma patients.”